{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:53:01Z","timestamp":1787226781603,"version":"build-2736575974"},"reference-count":27,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"unspecified","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["16\/16\/06"],"award-info":[{"award-number":["16\/16\/06"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,4,10]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n<jats:title>Introduction<\/jats:title>\n<jats:p>Excessive bleeding after childbirth (postpartum haemorrhage, PPH) affects 5% of births and causes 75\u2009000 maternal deaths worldwide annually. It is the leading cause of direct maternal deaths globally and continues to be a major cause of mortality in the UK. Oxytocin is the standard first-line treatment for atonic PPH. The PPH rate is increasing, and this may be partially related to the overuse of oxytocics in labour. Laboratory studies on myometrium suggest that repeated use of oxytocics leads to the saturation of oxytocin receptors and reduced therapeutic efficacy of oxytocin. Carboprost (a prostaglandin analogue) is usually reserved for second-line management of atonic PPH. A systematic review comparing the efficacy of carboprost and conventional uterotonics for PPH prophylaxis found that carboprost was associated with less blood loss, but around 15% of women experienced side effects. The study\u2019s aim is to compare intramuscular carboprost with intravenous oxytocin for the initial treatment of PPH. In addition, to assess the cost-effectiveness of both treatments, participants\u2019 views on the two treatments and the consent process.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods and analysis<\/jats:title>\n<jats:p>COPE is a double-blind, double-dummy, randomised controlled trial that aims to recruit 2000\u2009women (1:1 allocation, stratified by mode of birth) across 20 hospitals in the UK. Due to the emergency nature of PPH, COPE uses a research without prior consent (RWPC) model. Randomisation and treatment will occur if eligibility criteria are met once bleeding starts. Postnatal consent will be sought for disclosure of identifiable data and continued follow-up. Clinical efficacy outcomes will be collected at 24 and 48 hours or at hospital discharge, if sooner. Questionnaires will also be collected at 24 hours and 4 weeks postrandomisation. Cost-effectiveness will be based on the incremental cost per quality-adjusted life-year, calculated from the perspective of the NHS and personal social services.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Ethics and dissemination<\/jats:title>\n<jats:p>This study has been approved by the Coventry and Warwickshire Research Ethics Committee (REC) (18\/WM\/0227) and the Health Research Authority. Results will be disseminated via peer-reviewed publications.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Trial registration number<\/jats:title>\n<jats:p>\n<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"nct\" specific-use=\"clinicaltrial \" xlink:href=\"NCT16416766\">NCT16416766<\/jats:ext-link>\n.\n<\/jats:p>\n<\/jats:sec>","DOI":"10.1136\/bmjopen-2025-101255","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T15:49:18Z","timestamp":1746805758000},"page":"e101255","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Carboprost versus Oxytocin as the first-line treatment of primary postpartum haemorrhage (COPE): protocol for a phase IV, double-blind, double-dummy, randomised controlled trial and economic analysis"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct16416766","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct13204258","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2743-4637","authenticated-orcid":false,"given":"Charlotte","family":"Van Netten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirtana","family":"Vallabhaneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Hardwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilly","family":"Anumba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette L","family":"Briley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E","family":"Collis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Deja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathia","family":"Gkioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Gyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Hickey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Hinshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8247-7459","authenticated-orcid":false,"given":"Dyfrig A","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sion","family":"Kenyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1473-4956","authenticated-orcid":false,"given":"Tina","family":"Lavender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shireen","family":"Meher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catrin","family":"Plumpton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Robson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rosala-Hallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egle","family":"Saviciute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Shennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Siassakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9764-6876","authenticated-orcid":false,"given":"Jim","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Woolfall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrol","family":"Gamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Weeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"2025050822350936000_15.5.e101255.1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/1471-0528.13098","article-title":"The prevention and treatment of postpartum haemorrhage: what do we know, and where do we go to next?","volume":"122","author":"Weeks","year":"2015","journal-title":"BJOG"},{"key":"2025050822350936000_15.5.e101255.2","unstructured":"World Health Organization . A roadmap to combat postpartum haemorrhage between 2023 and 2030. Licence: CC BY-NC-SA 3.0 IGO. Geneva World Health Organization; 2023."},{"key":"2025050822350936000_15.5.e101255.3","unstructured":"Knight MN , Tuffnell D , Shakespeare J , et al . Saving lives, improving mothers\u2019 care - Lessons learned to inform maternity care from the UK and Ireland confidential enquiries into maternal deaths and morbidity 2013\u201315. Oxford: National Perinatal Epidemiology Unit, University of Oxford, 2017."},{"key":"2025050822350936000_15.5.e101255.4","unstructured":"Intrapartum care. NICE guideline. NG235. 2023."},{"key":"2025050822350936000_15.5.e101255.5","doi-asserted-by":"crossref","DOI":"10.1186\/1745-6215-15-258","article-title":"Cord pilot trial - immediate versus deferred cord clamping for very preterm birth (before 32 weeks gestation): study protocol for a randomized controlled trial","volume":"15","author":"Pushpa-Rajah","year":"2014","journal-title":"Trials"},{"key":"2025050822350936000_15.5.e101255.6","unstructured":"Gynaecologists RCoOa . Obtaining valid consent to participate in perinatal research where consent is time critical. Clinical governance advice No. 6a. London RCOG; 2016."},{"key":"2025050822350936000_15.5.e101255.7","doi-asserted-by":"crossref","DOI":"10.1186\/1745-6215-11-40","article-title":"The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial","volume":"11","author":"Shakur","year":"2010","journal-title":"Trials"},{"key":"2025050822350936000_15.5.e101255.8","doi-asserted-by":"crossref","DOI":"10.1186\/1745-6215-7-13","article-title":"Issues of informed consent for intrapartum trials: a suggested consent pathway from the experience of the Release trial [ISRCTN13204258]","volume":"7","author":"Vernon","year":"2006","journal-title":"Trials"},{"key":"2025050822350936000_15.5.e101255.9","first-page":"e106","article-title":"Prevention and Management of Postpartum Haemorrhage","volume":"124","author":"Mavrides","year":"2017","journal-title":"BJOG"},{"key":"2025050822350936000_15.5.e101255.10","unstructured":"Knight M , Kenyon S , Brocklehurst P , et al , eds. Saving lives, improving mothers\u2019 care - Lessons learned to inform future maternity care from the UK and Ireland confidential enquiries into maternal deaths and morbidity 2009-12. Oxford: National Perinatal Epidemiology Unit, University of Oxford, 2014."},{"key":"2025050822350936000_15.5.e101255.11","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000142709.04450.bd"},{"key":"2025050822350936000_15.5.e101255.12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/01.AOG.0000191529.52596.c0","article-title":"Minimum oxytocin dose requirement after cesarean delivery for labor arrest","volume":"107","author":"Balki","year":"2006","journal-title":"Obstet Gynecol"},{"key":"2025050822350936000_15.5.e101255.13","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.k3546","article-title":"Intramuscular versus intravenous oxytocin to prevent postpartum haemorrhage at vaginal delivery: randomised controlled trial","volume":"362","author":"Adnan","year":"2018","journal-title":"BMJ"},{"key":"2025050822350936000_15.5.e101255.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60348-0"},{"key":"2025050822350936000_15.5.e101255.15","article-title":"Prostaglandins for preventing postpartum haemorrhage","volume":"2012","author":"Tun\u00e7alp","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050822350936000_15.5.e101255.16","article-title":"Treatment for primary postpartum haemorrhage","volume":"2014","author":"Mousa","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050822350936000_15.5.e101255.17","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e318297d347"},{"key":"2025050822350936000_15.5.e101255.18","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/ael302"},{"key":"2025050822350936000_15.5.e101255.19","unstructured":"Why mothers die 1997 - 1999. The confidential enquiries into maternal deaths in the United Kingdom. 2001."},{"key":"2025050822350936000_15.5.e101255.20","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2015-309245"},{"key":"2025050822350936000_15.5.e101255.21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/1471-0528.15335","article-title":"Core outcome sets for prevention and treatment of postpartum haemorrhage: an international Delphi consensus study","volume":"126","author":"Meher","year":"2019","journal-title":"BJOG"},{"key":"2025050822350936000_15.5.e101255.22","doi-asserted-by":"publisher","DOI":"10.1177\/1049732315617444"},{"key":"2025050822350936000_15.5.e101255.23","doi-asserted-by":"crossref","DOI":"10.3402\/qhw.v9.26152","article-title":"What can \u201cthematic analysis\u201d offer health and wellbeing researchers?","volume":"9","author":"Braun","year":"2014","journal-title":"Int J Qual Stud Health Well-being"},{"key":"2025050822350936000_15.5.e101255.24","doi-asserted-by":"publisher","DOI":"10.1007\/s11135-021-01182-y"},{"key":"2025050822350936000_15.5.e101255.25","doi-asserted-by":"publisher","DOI":"10.2307\/798843"},{"key":"2025050822350936000_15.5.e101255.26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/ebmh.2.4.99","article-title":"Evaluating qualitative research","volume":"2","author":"Stiles","year":"1999","journal-title":"Evid Based Ment Health"},{"key":"2025050822350936000_15.5.e101255.27","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-101255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T15:49:23Z","timestamp":1746805763000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-101255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,8]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/bmjopen-2025-101255"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-101255","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}